FDA Approves CAPECITABINE — BluePoint Laboratories

BluePoint Laboratories has received marketing authorization from the FDA for its generic version of CAPECITABINE, positioning the firm to capturemarket share amid expected competition following the patent expiration of the branded drug. This ANDA approval allows the company to sell the oral anticancer agent and capitalize on the growing demand for cost-effective oncology treatments.